SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following its inclusion as an awardee under the Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program, signaling potential for significant defense contracts. This development, coupled with the stock's recent achievement of closing above a triple-digit price point, is fueling widespread community discussions about short squeeze potential and long-term growth for its direct-to-smartphone satellite technology.

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings Ltd. (SPHL) is trending with explosive price action, largely driven by its low share float and a recently announced partnership for solar-ready homes in Singapore. The community is keenly comparing SPHL to other high-volatility microcap runners, actively discussing the potential for a significant short squeeze and parabolic gains.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital (GLXY) is buzzing after securing ERCOT approval to double its Helios data center's power capacity to over 1.6 Gigawatts, fueling anticipation for major AI hyperscaler partnerships and a significant re-rating as an infrastructure play. The community is actively debating whether this landmark development will finally decouple the stock from Bitcoin's volatility and drive substantial analyst upgrades. While many see GLXY as a deeply undervalued AI and digital finance hybrid, some vocal skeptics remain frustrated by past performance and dilution concerns.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major talking point ahead of its upcoming earnings, with significant community debate swirling around a potential acquisition of Warner Bros. Discovery. Many anticipate a short squeeze and rebound, fueled by a new Sony Pictures content deal and unconfirmed rumors of Berkshire Hathaway's interest. However, others express concern over the WBD deal's financial implications and regulatory scrutiny, which they believe is heavily weighing on the stock, with investors keenly watching for management's clarity and earnings performance.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE CRYPTO is trending with intense community enthusiasm, driven by social media mentions and a strong 'pack' mentality. Investors are actively discussing its 'chosen one' status, often linking it to the AI meta and the 'Grok dog' narrative, highlighting its community-owned structure and perceived bullish sentiment.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as its J.P. Morgan Healthcare Conference presentation fuels intense shareholder debate. Many investors voice deep frustration over perceived management inaction and delayed partnerships for its flu/COVID combo and Matrix-M oncology applications. Amidst high short interest, the community eagerly anticipates a new major partnership or a potential proxy fight from major investor Shah Capital to unlock the company's valuation.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

ProShares UltraPro QQQ is currently seeing heightened discussion amidst conflicting signals from tech earnings, particularly Oracle's recent miss and increased AI-related spending, alongside mixed labor data. Community sentiment is divided between those actively buying dips in anticipation of a potential Federal Reserve rate cut and a year-end rally, and others expressing caution over perceived market manipulation and stretched tech valuations. As a leveraged Nasdaq 100 ETF, TQQQ remains highly sensitive to these swings, prompting active debate on its short-term volatility versus its long-term growth potential within the evolving AI landscape.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending after its CEO signaled broad strategic interest in the company at a major healthcare conference, coinciding with a peer pharmaceutical CEO's remarks on significant M&A spending in the obesity sector. The community is actively debating the potential for a major partnership or acquisition, driven by recent positive clinical data for its lead weight-loss drug and its perceived strong profile. This positions VKTX as a key player in the rapidly expanding and competitive market for next-generation obesity treatments.

Vanguard Malvern Funds - Vanguard Short-Term Inflation-Protected Securities Index Fund

Vanguard Short-Term Inflation-Protected Securities ETF

VTIP, an inflation-protected ETF, is drawing attention as market participants question the accuracy of recent inflation data and anticipate potential upward revisions. The community is actively discussing its role as an inflation hedge, with some observing recent price movements while others consider current levels as a favorable entry. This conversation unfolds amid broader concerns about U.S. debt and shifting real yields.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is gaining significant traction following a strategic CEO transition focused on scaling its high-energy-density silicon-anode battery production and expanding its South Korea manufacturing alliance. The community intensely debates the stock's future, anticipating major defense and commercial contracts while navigating market volatility and persistent discussions around short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q4 Earnings Estimate for CRDF Issued By Noble Financial

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Analysts at Noble Financial issued their Q4 2025 earnings per share estimates for Cardiff Oncology in a research report issued to clients and...

Noble Financial Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF)

Noble Financial started coverage on Cardiff Oncology in a research report on Monday. They issued an "outperform" rating and a $12.00 price objective for the company...

Stock Traders Purchase High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF)

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the target of unusually large options trading on Tuesday. Traders purchased 2,314 call options on the stock. This represents an increase of...

Flputnam Investment Management Co. Purchases 543,370 Shares of Cardiff Oncology, Inc. $CRDF

Flputnam Investment Management Co. lifted its position in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 1,008.8% during the 3rd quarter, according to the company in its most recent Form 13F...

Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Rating of "Hold" by Brokerages

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) have been given an average recommendation of "Hold" by the five analysts that are currently covering the firm, MarketBeat reports. One...

FY2025 Earnings Forecast for CRDF Issued By Zacks Small Cap

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Zacks Small Cap issued their FY2025 earnings per share (EPS) estimates for shares of Cardiff Oncology in a report issued on Tuesday, December 9th...

Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Rating of "Moderate Buy" by Brokerages

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat Ratings reports...

What is HC Wainwright's Estimate for CRDF FY2025 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities researchers at HC Wainwright upped their FY2025 earnings estimates for Cardiff Oncology in a note issued to investors on Wednesday...

Cardiff Oncology (NASDAQ:CRDF) Issues Quarterly Earnings Results

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) released its earnings results on Thursday. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20...

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -10.53% and -19.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Cardiff Oncology Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$2.79
Prev Close	$2.81
Open	$2.80
Dividend Yield	0.00%
50-Day Moving Average	$2.48
Beta	1.43
Avg. Volume	1.07M
PE Ratio	-3.52

52-Week High	$4.99
52-Week Low	$1.90
Market Capitalization	$189.28M
EPS (Annual)	-$0.9539
Price to Book	3.84
Revenue Per Employee	$20,696.97
Enterprise Value/EBITDA	N/A

CRDF
Cardiff Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRDF News

CRDFCardiff Oncology Inc